Company: WHWK
Filing Date: 2025-04-25
Form Type: 424B5
Source: 0001193125-25-097064
Chunk: 11

Company: Whitehawk Therapeutics, Inc.
Filing Date: 2025-04-25
Form: 424B5
Chunk 11
---
 TD
Cowen at any time throughout the term of the sales agreement. The number of shares that are sold by TD Cowen after delivering a placement notice will fluctuate based on the market price of the common shares during the sales period and limits we set
with TD Cowen. Because the price per share of each share sold will fluctuate based on the market price of our common stock during the sales period, it is not possible at this stage to predict the number of shares that will be ultimately issued.

S-9

SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS This prospectus supplement, including the documents incorporated by reference herein, contains forward-looking statements concerning our business, operations and financial performance and condition, as well as our plans, objectives and expectations for our business operations and financial performance and condition. Any statements contained, or incorporated by reference, herein that are not statements of historical facts may be deemed to be forward-looking statements. In some cases, you can identify forward-looking statements by terminology such as “aim,” “anticipate,” “assume,” “believe,” “contemplate,” “continue,” “could,” “due,” “estimate,” “expect,” “goal,” “intend,” “may,” “objective,” “plan,” “predict,” “potential,” “positioned,” “seek,” “should,” “target,” “will,” “would,” and other similar expressions that are predictions of or indicate future events and future trends, or the negative of these terms or other comparable terminology. These forward-looking statements include, but are not limited to, statements about:

| ∎ |     | our estimates regarding expenses, capital requirements, needs for additional financing and the period over which we                                                                                                                                 
 anticipate our existing cash and cash equivalents will be sufficient to fund our operating expenses and capital expenditure requirements, including our belief that, based on our current plans, our existing cash, cash equivalents and short-term 
 investments will enable us to conduct our planned operations into 2028;                                                                                                                                                                             |

| ∎ |     | our ability to obtain and maintain regulatory approval for our portfolio of three next generation ADC Therapies or any                                      
 other product candidates we may develop in the future, and any related restrictions, limitations or warnings in the label of an approved product candidate; |

| ∎ |     | the timing, progress and results of preclinical studies and clinical trials for our programs and product candidates                                                                                                                                    
 (including our anticipated timing of submitting three IND applications for the ADC Therapies with the FDA in the coming